Navigation Links
PDL BioPharma Announces Two $0.50 Dividends in 2010
Date:1/28/2010

INCLINE VILLAGE, Nev., Jan. 28 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it will pay two special dividends to its stockholders in 2010. Each of the dividends will be $0.50 per share. The first special dividend will be paid on April 1, 2010 to all stockholders who own shares of PDL on March 15, 2010, the Record Date. The second special dividend will be paid on October 1, 2010 to all stockholders who own shares of PDL on September 15, 2010, the Record Date.

Stockholders desiring to purchase shares with rights to the special dividend must ensure that their trades are executed prior to the "ex-dividend" date and settle prior to the Record Date. NASDAQ will establish an ex-dividend date that is generally three business days prior to the Record Date. You should consult with your broker or financial advisor regarding your specific situation.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

As all dividend payments are subject to compliance with legal requirements, dividend announcements constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Important factors that could impair the value of the Company's royalty assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's 2008 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2009. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

SOURCE PDL BioPharma

RELATED LINKS
http://www.pdl.com

'/>"/>

SOURCE PDL BioPharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. Commissions its Commercial-Scale Lyophilizer
2. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
3. Seven More Biopharmaceutical Research Companies Join PhRMA
4. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
5. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
6. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
7. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
8. Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training
9. OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners
10. Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
11. Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... CA 92660 (PRWEB) , ... July 26, ... ... Loss Prevention for on-premises, off and in the cloud ; today announced the ... and scientific algorithms within a simple to use control console for Data Discovery, ...
(Date:7/26/2017)... ... 26, 2017 , ... “We are thrilled to be partnering with Six Month ... an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing patients the ... bring more Six Month Smiles patients to their providers.” , Each month, over 25,000 ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... IDC-Eating ... Medical Director for the treatment program located in Royal Oak, Michigan. IDC, ... investors who are focused on providing the highest standards in the field of eating ...
(Date:7/26/2017)... Monroe, LA (PRWEB) , ... July 26, 2017 , ... ... - 2:00 p.m. at Charles Johnson Park at 3313 Bernstein Park Drive in Monroe ... Amnesty Rally is to help reduce gun violence throughout Monroe. Citizens can ...
(Date:7/26/2017)... Springs, FL (PRWEB) , ... July 26, 2017 ... ... the nation’s leading innovative specialty pharmacies, has released an updated version of the ... the latest guidelines for treating chronic hepatitis C virus (HCV) infection. All of ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
(Date:7/11/2017)... , July 11, 2017  The global market ... revenues of approximately $394.1 million in 2016.  Although in ... of solid growth, in particular as a result of ... practice, and the recent introduction of a significant number ... for less-invasive testing of tumor biomarkers to guide treatment ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
Breaking Medicine Technology: